Saturday, February 24

LungLife AI announces success in Validation of LungLB in multi-site, prospective clinical study

–News Direct–

LungLife AI CEO Dr. Paul Pagano joined Steve Darling from Proactive to discussed the groundbreaking lung cancer detection technology developed by the company.

LungLife AI is dedicated to addressing the critical issue of early detection in lung cancer, which remains the leading cause of cancer-related deaths. Dr. Pagano highlighted the sobering statistic that 80% of lung cancer cases are detected too late, contributing to the high mortality rate associated with this disease.

The company's lung lb test, which has recently undergone successful validation, is poised to revolutionize the early detection of lung cancer by addressing the challenge of evaluating small nodules under 15 millimetres in size. Early intervention is crucial in improving patient outcomes, and the lung lb test is designed to meet this unmet need.

Physicians have expressed excitement about the potential of this test to transform the landscape of lung cancer detection. Unlike existing methods, the lung lb test takes a unique approach by examining circulating genetically abnormal cells in the blood. This innovative approach offers a complementary and highly sensitive means of detecting lung cancer, enhancing the chances of early intervention and improved patient prognosis.

Dr. Pagano discussed the competitive landscape, emphasizing LungLife AI's patented methods and proprietary technologies that set their approach apart in the field of lung cancer detection.

Looking ahead, LungLife AI plans a methodical introduction of the lung lb test through an early access program, ensuring a seamless transition into healthcare settings. The next six to twelve months will involve a commercial proof of concept, with the company collaborating with hospital sites and working towards securing coverage from insurance providers.

The potential life-saving impact of LungLife AI's technology and their strategic approach to making it accessible to patients and healthcare providers mark a significant contribution to advancing the field of lung cancer detection.

The company's dedication to improving early detection rates and ultimately reducing the mortality associated with this devastating disease underscores their commitment to patient care and well-being.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/lunglife-ai-announces-success-in-validation-of-lunglb-in-multi-site-prospective-clinical-study-490243098

LungLife AI Inc

comtex tracking

COMTEX_447352084/2655/2024-02-05T14:27:05

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No A News Week journalist was involved in the writing and production of this article.